Skip to main content
Caplight Logo









Biovista

Biovista

Private
Charlottesville, VirginiaHealthcare & Life Scienceshttps://biovista.com/

Last Round

Grant

Mar 6, 2012

Total Funding Raised

$500,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Biovista is a biotechnology company that has developed an artificial intelligence-based platform intended to deliver custom drug repositioning, drug de-risking, and clinical hold services for the biopharma industry.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Medical AI, Biotechnology, Healthcare Analytics, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS, Government Contracts, Data as a Service, Freemium

AI Layer

Application

Keywords

drug repositioningdrug repurposingAI drug discoverydrug de-riskingin silico drug discoverycomputational drug discoveryadverse event predictionAI platformbiopharmaceutical servicesmechanism of actionpersonalized medicinebiomedical literature miningorphan diseasesneurodegenerative diseasesoncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biovista Comparables

Compare Biovista with similar companies based on industry and business-model similarity.

Biovista comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delta4
90%
Purposeful
84%
Healx
80%

Biovista Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 6, 2012
GrantMay 5, 2011

Key People

Founding team and executive leadership

Graham Anthony

Chief Financial Officer, Board Member & Investor

Executive Team

Biovista Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    Monthly visitors increased 123% MoM, reaching 4.8K.

  • Feb 21, 2025

    Grew 31% QoQ from 16 to 21 employees.

Biovista Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Biovista Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Biovista's valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottesville, Virginia
Employee Range23
Year Founded1999
Last FundingMar 6, 2012

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?